Search
CMP-001
Indications:
- treatment of pembrolizumab-resistant cutaneous melonoma
Dosage:
- direct intratumoral injection
* requires accessible lesion such as a skin lesion or a palpable subcutaneous lesion, or a lymph node
Mechanism of action:
- synthetic immunostimulatory DNA molecule (CpG-A) encased in a nonreplicating virus-like particle that protects the DNA from degradation
- stimulates TLR9 activity
- activation of tumor-associated dendritic cells
- induction of an IFN & antitumor T-cell activation
General
antineoplastic agent (chemotherapeutic agent)
References
- Bankhead C
Drug May Reverse Anti-PD-1 Resistance in Melanoma.
Responses in 22% of resistant patients with TLR9 agonist.
MedPage Today. April 19, 2018
https://www.medpagetoday.com/meetingcoverage/aacr/72435
- Milhem M, et al
Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001,
in combination with pembrolizumab can reverse resistance to
PD-1 inhibition in a phase Ib trial in subjects with advanced
melanoma.
American Association for Cancer Research (AACR 2018)
Abstract CT144